Tissue dyslipidemia in salmonella-infected rats treated with amoxillin and pefloxacin

Lipids in Health and Disease

Oladipo Ademuyiwa²  Elizabeth A Balogun²  Olusola A Talabi⁴  David A Ojo³  Solomon O Rotimi¹ 

[1] Biochemistry Unit, Department of Biological Sciences, Covenant University, Ota, Nigeria;Department of Biochemistry, University of Agriculture, Abeokuta, Nigeria;Department of Microbiology, University of Agriculture, Abeokuta, Nigeria;Medical Centre, University of Agriculture, Abeokuta, Nigeria

关键词: Pefloxacin;    Amoxicillin;    Phospholipidosis;    Cholesterogenesis;    Salmonellosis;   

Others  :  1160150
DOI  :  10.1186/1476-511X-11-152

 received in 2012-04-12, accepted in 2012-11-06,  发布年份 2012

【 摘 要 】

Background

This study investigated the effects of salmonella infection and its chemotherapy on lipid metabolism in tissues of rats infected orally with Salmonella typhimurium and treated intraperitoneally with pefloxacin and amoxillin.

Methods

Animals were infected with Salmonella enterica serovar Typhimurium strain TA 98. After salmonellosis was confirmed, they were divided into 7 groups of 5 animals each. While one group served as infected control group, three groups were treated with amoxillin (7.14 mg/kg body weight, 8 hourly) and the remaining three groups with pefloxacin (5.71mg/kg body weight, 12 hourly) for 5 and 10 days respectively. Uninfected control animals received 0.1ml of vehicle. Rats were sacrificed 24h after 5 and 10 days of antibiotic treatment and 5 days after discontinuation of antibiotic treatment. Their corresponding controls were also sacrificed at the same time point. Blood and tissue lipids were then evaluated.

Results

Salmonella infection resulted in dyslipidemia characterised by increased concentrations of free fatty acids (FFA) in plasma and erythrocyte, as well as enhanced cholesterogenesis, hypertriglyceridemia and phospholipidosis in plasma, low density lipoprotein-very low density lipoprotein (LDL-VLDL), erythrocytes, erythrocyte ghost and the organs. The antibiotics reversed the dyslipidemia but not totally. A significant correlation was observed between fecal bacterial load and plasma cholesterol (r=0.456, p<0.01), plasma triacyglycerols (r=0.485, p<0.01), plasma phospholipid (r=0.414, p<0.05), plasma free fatty acids (r=0.485, p<0.01), liver phospholipid (r=0.459, p<0.01) and brain phospholipid (r=0.343, p<0.05).

Conclusion

The findings of this study suggest that salmonella infection in rats and its therapy with pefloxacin and amoxillin perturb lipid metabolism and this perturbation is characterised by cholesterogenesis.

【 授权许可】

   
2012 Rotimi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Levine MM, Tacket CO, Sztein MB: Host-Salmonella interaction: human trials. Microbes Infect 2001, 3:1271-1279.
• [2]Parry CM: Antimicrobial drug resistance in Salmonella enterica. Curr Opin Infect Dis 2003, 16:467-472.
• [3]Darwin KH, Miller VL: Molecular basis of the interaction of Salmonella with the intestinal mucosa. Clin Microbiol Rev 1999, 12:405-428.
• [4]Clark MA, Jepson MA, Simmons NL, Hirst BH: Preferential interaction of Salmonella typhimurium with mouse Peyer's patch M cells. Res Microbiol 1994, 145:543-552.
• [5]Mohanty S, Gaind R, Sehgal R, Chellani H, Deb M: Neonatal sepsis due to Salmonella Typhi and Paratyphi A. J Infect Dev Ctries 2009, 3:633-638.
• [6]Newcomb D, Bolgos G, Green L, Remick DG: Antibiotic treatment influences outcome in murine sepsis: mediators of increased morbidity. Shock 1998, 10:110-117.
• [7]Yildiran A, Siga E, Baykal S, Okten A: Sepsis and multiple brain abscesses caused by Salmonella paratyphi B in an infant: successful treatment with sulbactam-ampicillin and surgical drainage. Turk J Pediatr 2001, 43:85-87.
• [8]Young DK, Reid KM: Salmonella sepsis in ulcerative colitis: report of a case and review of the literature. J Am Osteopath Assoc 1987, 87:488-492.
• [9]Ogunlesi TA, Ogunfowora OB, Osinupebi O, Olanrewaju DM: Changing trends in newborn sepsis in Sagamu, Nigeria: bacterial aetiology, risk factors and antibiotic susceptibility. J Paediatr Child Health 2011, 47:5-11.
• [10]Carre JE, Singer M: Cellular energetic metabolism in sepsis: the need for a systems approach. Biochim Biophys Acta 2008, 1777:763-771.
• [11]Fischer JE, Hasselgren PO: Cytokines and glucocorticoids in the regulation of the "hepato-skeletal muscle axis" in sepsis. Am J Surg 1991, 161:266-271.
• [12]Hasselgren PO, Talamini M, James JH, Fischer JE: Protein metabolism in different types of skeletal muscle during early and late sepsis in rats. Arch Surg 1986, 121:918-923.
• [13]Kovalenko AN, Zhdanov KV, Volzhanin VM, Shishkin MK, Tokmakov VS, Karpov AV, Murachev AA, Kondratenok VA: Features of clinic, diagnostics and treatment of typhoid fever in young patients. Voen Med Zh 2011, 332:33-39.
• [14]Makhnev MV: Efficacy of various antimicrobial agents in the treatment of epidemic typhoid fever. Antibiot Khimioter 2003, 48:27-34.
• [15]Basnyat B: Typhoid fever in the United States and antibiotic choice. JAMA 2010, 303:34. author reply 34–35
• [16]Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, Mercier JC, Offenstadt G, Regnier B: Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 1995, 274:968-974.
• [17]Iperepolu OH, Entonu PE, Agwale SM: A review of the disease burden, impact and prevention of typhoid fever in Nigeria. West Afr J Med 2008, 27:127-133.
• [18]Havelaar AH, Garssen J, Takumi K, Koedam MA, Dufrenne JB, van Leusden FM, de La Fonteyne L, Bousema JT, Vos JG: A rat model for dose–response relationships of Salmonella Enteritidis infection. J Appl Microbiol 2001, 91:442-452.
• [19]Naughton PJ, Grant G, Spencer RJ, Bardocz S, Pusztai A: A rat model of infection by Salmonella typhimurium or Salm. enteritidis. J Appl Bacteriol 1996, 81:651-656.
• [20]Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340:448-454.
• [21]Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR: Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992, 74:1045-1052.
• [22]Sammalkorpi K, Valtonen V, Kerttula Y, Nikkila E, Taskinen MR: Changes in serum lipoprotein pattern induced by acute infections. Metabolism 1988, 37:859-865.
• [23]Tiirola T, Jauhiainen M, Erkkila L, Bloigu A, Leinonen M, Haasio K, Laitinen K, Saikku P: Effect of pravastatin treatment on Chlamydia pneumoniae infection, inflammation and serum lipids in NIH/S mice. Int J Antimicrob Agents 2007, 29:741-742.
• [24]Nonogaki K, Moser AH, Pan XM, Staprans I, Grunfeld C, Feingold KR: Lipoteichoic acid stimulates lipolysis and hepatic triglyceride secretion in rats in vivo. J Lipid Res 1995, 36:1987-1995.
• [25]Memon RA, Grunfeld C, Moser AH, Feingold KR: Tumor necrosis factor mediates the effects of endotoxin on cholesterol and triglyceride metabolism in mice. Endocrinology 1993, 132:2246-2253.
• [26]Hardardottir I, Grunfeld C, Feingold KR: Effects of endotoxin and cytokines on lipid metabolism. Curr Opin Lipidol 1994, 5:207-215.
• [27]Hardardottir I, Sipe J, Moser AH, Fielding CJ, Feingold KR, Grunfeld C: LPS and cytokines regulate extra hepatic mRNA levels of apolipoproteins during the acute phase response in Syrian hamsters. Biochim Biophys Acta 1997, 1344:210-220.
• [28]Xu N, Nilsson A: Endotoxin inhibits catabolism of low density lipoproteins in vivo: an experimental study in the rat. Scand J Clin Lab Invest 1996, 56:53-61.
• [29]Wright LC, Nouri-Sorkhabi MH, May GL, Danckwerts LS, Kuchel PW, Sorrell TC: Changes in cellular and plasma membrane phospholipid composition after lipopolysaccharide stimulation of human neutrophils, studied by 31P NMR. Eur J Biochem 1997, 243:328-335.
• [30]Sakaguchi O, Sakaguchi S: Alterations of lipid metabolism in mice injected with endotoxin. Microbiol Immunol 1979, 23:71-85.
• [31]Ademuyiwa O, Agarwal R, Chandra R, Behari JR: Lead-induced phospholipidosis and cholesterogenesis in rat tissues. Chem Biol Interact 2009, 179:314-320.
• [32]Kojima M, Sekikawa K, Nemoto K, Degawa M: Tumor necrosis factor-alpha independent downregulation of hepatic cholesterol 7alpha hydroxylase gene in mice treated with lead nitrate. Toxicol Sci 2005, 87(2):537-542.
• [33]Jiang XC, Bruce C, Mar J, Lin M, Ji Y, Francone OL, Tall AR: Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest 1999, 103:907-914.
• [34]Botham KM: Lipid transport and storage. In Harper’s Illustrated Biochemistry. 27th edition. Edited by Murray RK, Granner DK, Rodwell VW. Boston: McGraw-Hill; 2006:217-229.
• [35]Liu SH, Sheu TJ, Lin RH, Lin-Shiau SY: The in vivo effect of lipopolysaccharide on the spontaneous release of transmitter from motor nerve terminals. Br J Pharmacol 1995, 116:1757-1760.
• [36]Feingold KR, Memon RA, Moser AH, Shigenaga JK, Grunfeld C: Endotoxin and interleukin-1 decrease hepatic lipase mRNA levels. Atherosclerosis 1999, 142:379-387.
• [37]Sawada H, Takami K, Asahi S: A toxicogenomic approach to drug-induced phospholipidosis: An analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci 2005, 83:282-292.
• [38]Hung CR, Wang PS: Gastric oxidative stress and hemorrhagic ulcer in Salmonella typhimurium-infected rats. Eur J Pharmacol 2004, 491:61-68.
• [39]van Ampting MT, Schonewille AJ, Vink C, Brummer RJ, van der Meer R, Bovee-Oudenhoven IM: Intestinal barrier function in response to abundant or depleted mucosal glutathione in Salmonella-infected rats. BMC Physiol 2009, 9:6.
• [40]Gidez LI, Miller GJ, Burstein M, Slagle S, Eder HA: Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. J Lipid Res 1982, 23:1206-1223.
• [41]Folch J, Lees M, Sloane Stanley GH: A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957, 226:497-509.
• [42]Stewart JC: Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem 1980, 104:10-14.
• [43]Holmes DT, Frohlich J, Buhr KA: The concept of precision extended to the atherogenic index of plasma. Clin Biochem 2008, 41:631-635.
• [44]Soloni FG, Sardina LC: Colorimetric microdetermination of free fatty acids. Clin Chem 1973, 19:419-424.
• [45]Brunk SD, Swanson JR: Colorimetric method for free fatty acids in serum validated by comparison with gas chromatography. Clin Chem 1981, 27:924-926.
• [46]Rose HG, Oklander M: Improved procedure for the extraction of lipids from human erythrocytes. J Lipid Res 1965, 6:428-431.
• [47]Eder K, Kirchgessner M: The effect of zinc deficiency on erythrocyte membrane lipids of force-fed rats receiving a diet containing coconut oil or fish oil. J Trace Elem Electrolytes Health Dis 1994, 8:63-73.
• [48]Kriketos AD, Furler SM, Gan SK, Poynten AM, Chisholm DJ, Campbell LV: Multiple indexes of lipid availability are independently related to whole body insulin action in healthy humans. J Clin Endocrinol Metab 2003, 88:793-798.
• [49]Hanahan DJ, Ekholm JE: The preparation of red cell ghosts (membranes). Methods Enzymol 1974, 31:168-172.
• [50]Rao AV, Ramakrishnan S: Indirect assessment of hydroxymethylglutaryl-CoA reductase (NADPH) activity in liver tissue. Clin Chem 1975, 21:1523-1525.